Medline outlines 2027 high single-digit sales growth and $1B buyback
FROM THE WIRE · SEEKINGALPHA.COM
Medline Q3 2026 earnings: sales guidance rises, EBITDA holds, buyback launches, and 2027 margin pressures emerge.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRaised sales guidance and a new buyback are relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Medline raised sales guidance in Q3 2026.
- 02EBITDA held steady in the reported results.
- 03A $1B share repurchase program was launched.